Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 EUROPE PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) IN THE AGE OF PATIENT CENTRICITY
5.1.2 GROWING DEMAND FOR ECOA DUE TO ITS CAPABILITY TO COLLECT LARGE AMOUNTS OF DATA WHILE SIMULTANEOUSLY ENSURING HIGH QUALITY
5.1.3 EMERGING TECHNOLOGICAL TRENDS BY PROVIDING A GREATER UNDERSTANDING OF EDC AND ECOA/EPRO PENETRATION IN PHARMACEUTICAL MARKETS
5.1.4 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY
5.1.5 RISING NEED TOWARDS ELECTRONIC DATA CAPTURING FOR EFFICIENCY OF CLINICAL TRIALS
5.1.6 COST-EFFICIENCY AND RELIABILITY PROVIDED BY THE ECOA
5.1.7 RISING NUMBER OF CLINICAL TRIALS REGULATED BY FDA AND APPROVED BY INSTITUTIONAL REVIEW BOARD (IRB) FOR PATIENT SAFETY IN MULTI-CENTER TRIALS
5.2 RESTRAINTS
5.2.1 HIGH INITIAL COSTS ASSOCIATED WITH THE IMPLEMENTATION AND UTILIZATION OF THE SYSTEMS
5.2.2 LACK OF AWARENESS ABOUT REGULATIONS RELATED TO THE DATA MANAGEMENT
5.3 OPPORTUNITIES
5.3.1 RISING LEVELS OF INNOVATIONS AND ADVANCED TECHNOLOGIES
5.3.2 INCREASING PARTNERSHIPS AND COLLABORATIONS FOR CLINICAL RESEARCHES
5.3.3 DIGITIZATION OF CLINICAL TRIALS AIMS AT PERFORMING THEIR END-TO-END DIGITAL TRANSFORMATION
5.3.4 INCREASING COLLABORATION BETWEEN INDUSTRY AND GOVERNMENT FOR CLINICAL TRIALS UNDER GOVERNMENT POLICIES
5.4 CHALLENGES
5.4.1 LACK OF WELL-TRAINED PROFESSIONALS FOR ACCURATE DATA INTERPRETATION
5.4.2 LACK OF PROPER IT INFRASTRUCTURE IN MANY DEVELOPING COUNTRIES
6 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 ON-PREMISE SOLUTIONS
6.3 CLOUD BASED SOLUTIONS
6.4 WEB BASED SOLUTIONS
7 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH
7.1 OVERVIEW
7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO)
7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO)
7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO)
7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO)
8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER
8.1 OVERVIEW
8.2 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS
8.3 HOSPITALS AND TRANSPLANT CENTERS
8.4 COMMERCIAL SERVICE PROVIDERS
9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM
9.1 OVERVIEW
9.2 CONTRACT RESEARCH ORGANIZATIONS
9.3 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
9.4 MEDICAL DEVICE MANUFACTURERS
9.5 HOSPITALS AND CLINICAL LABORATORIES
9.6 CONSULTING SERVICE COMPANIES
9.7 RESEARCH AND ACADEMIA
9.8 OTHERS
10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET, BY REGION
10.1 EUROPE
10.1.1 U.K.
10.1.2 GERMANY
10.1.3 SPAIN
10.1.4 FRANCE
10.1.5 ITALY
10.1.6 SWITZERLAND
10.1.7 NETHERLANDS
10.1.8 BELGIUM
10.1.9 TURKEY
10.1.10 RUSSIA
10.1.11 REST OF EUROPE
11 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY LANDSCAP
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 ORACLE
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 PAREXEL INTERNATIONAL CORPORATION
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 ERT CLINICAL
13.3.1 COMPANY SNAPSHOT
13.3.2 COMPANY SHARE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 DASSAULT SYSTÈMES
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 BIOCLINICA
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 IBM CORPORATION
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 CLINICAL INK
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENTS
13.8 KAYENTIS
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 ANJU SOFTWARE, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENTS
13.1 ARISEUROPE
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 ECLINICAL SOLUTIONS LLC
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 SIGNANT HEALTH
13.12.1 COMPANY SNAPSHOT
13.12.2 SOLUTION PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.13 WIRB-COPERNICUS GROUP
13.13.1 COMPANY SNAPSHOT
13.13.2 SERVICE PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.14 YPRIME LLC
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 2 EUROPE ON-PREMISE SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 EUROPE CLOUD BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 4 EUROPE WEB BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 6 EUROPE CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 7 EUROPE PATIENT REPORTED OUTCOME ASSESSMENT (PRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 EUROPE OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 EUROPE PERFORMANCE OUTCOME ASSESSMENT (PERFO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 11 EUROPE RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 12 EUROPE HOSPITALS AND TRANSPLANT CENTERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 13 EUROPE COMMERCIAL SERVICE PROVIDERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 14 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 15 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 EUROPE PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 17 EUROPE MEDICAL DEVICE MANUFACTURERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 18 EUROPE HOSPITALS AND CLINICAL LABORATORIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 19 EUROPE CONSULTING SERVICE COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 20 EUROPE RESEARCH AND ACADEMIA IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 EUROPE OTHERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 23 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 24 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 25 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 26 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 27 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 28 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 29 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 30 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 31 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 32 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 33 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 34 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 35 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 36 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 37 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 38 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 39 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 40 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 41 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 42 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 43 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 44 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 45 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 46 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 47 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 48 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 49 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 50 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 51 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 52 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 53 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 54 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 55 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 56 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 57 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 58 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 59 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 60 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 61 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 62 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 63 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 64 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 65 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 66 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 67 REST OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
List of Figure
LIST OF FIGURES
FIGURE 1 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION
FIGURE 2 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION
FIGURE 10 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY IS EXPECTED TO DRIVE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 ON-PREMISE SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET
FIGURE 13 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT, 2020
FIGURE 14 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY APPROACH, 2020
FIGURE 15 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY END USER, 2020
FIGURE 16 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PLATFORM, 2020
FIGURE 17 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020)
FIGURE 18 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020)
FIGURE 19 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028)
FIGURE 20 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028)
FIGURE 21 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028)
FIGURE 22 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%)
